Τελευταία ενημέρωση :
19/11/2024
Ερευνητικές ομάδες - Universidad Complutense de Madrid,Facultad de Farmacia   pdf  
Ισπανία
πανεπιστήμιο
Universidad Complutense de Madrid,Facultad de Farmacia
Madrid
Βιβλιογραφία   Βιβλιογραφία   (12)  
1
Stability of daptomycin reconstituted vials and infusion solutions.
Ferrandez J, Sanchez R, Diaz D, Diaz M, Estevan M, Garcia T. (sanchez@salud.madrid.org)
EJHP - 2018 - ; 25: 107-110.
2
Stability of carboplatin infusion solutions used in desensitization protocol.
Vazquez-Sanchez R, Sanchez-Rubio-Ferrandez J, Cordoba-Diaz D, Cordoba-Diaz M, Molina-Garcia T. (rovazsan@hotmail.com)
J Oncol Pharm Practice - 2018 - 25,5:1076?1081
3
Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine.
Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. ()
J Palliat Med - 2010 - ; 13, 3: 273-277.
4
Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability.
Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. (ebarcia@farm.ucm.es)
Support Care Cancer - 2007 - ; 15: 57-62.
5
Compatibility and stability of tramadol and dexamethasone in solution and its use in terminally ill patients.
Negro S, Salama A, S?nchez Y, AzuaraM.L, Barcia B. (soneal@farm.ucm.es)
J Clin Pharm Ther - 2007 - ; 32: 441-444.
6
Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients.
Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. (soneal@farm.ucm.es )
Int J Pharm - 2006 - ; 307: 278-284.
7
Compatibility and stability of furosemide and dexamethasone combined in infusion solutions.
Negro S, Rendon AL, Azuara ML, S?nchez Y, Fern?ndez-Carballido A, Barcia E. ( soneal@farm.ucm.es)
Arzneimittel Forschung - 2006 - ; 56, 10: 714-720.
8
Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide.
Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S. ()
Support Care Cancer - 2005 - ; 13, 4: 239-245.
9
Stability of tramadol and haloperidol for continuous infusion at home.
Negro S, Martin A, Azuara ML, Sanchez Y, Barcia E. ()
J Pain Symptom Manage - 2005 - ; 30: 192-199.
10
Stability study of an aqueous formulation of captopril at 1 mg/ml.
Escribano Garcia MJ, Torrado Duran S, Torrado Duran JJ. (torrado2@farm.ucm.es)
Farm Hosp - 2005 - ; 29: 30-36.
11
Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.
Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. ()
Support Care Cancer - 2003 - ; 11, 2: 107-113.
12
Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care.
Azuara ML, Sanchez Y, Reyes R, Barcia E. (soneal @eucmax.sim.ucm.es)
Support Care Cancer - 2001 -

Καταστάσεις   μόρια που μελετήθηκαν   (11)  
Αντιϋπερτασικό Πόσιμο διάλυμα Captopril
φάρμακο κατά του καρκίνου Ενέσιμο Carboplatin
Αντιβιοτικό Ενέσιμο Daptomycin
Αντιφλεγμονώδες Ενέσιμο Dexamethasone sodium phosphate
Διουρητικό Ενέσιμο Furosemide
Νευροληπτικό Ενέσιμο Haloperidol lactate
Αντιεμετικό Ενέσιμο Metoclopramide hydrochloride
Αγχολυτικό Ενέσιμο Midazolam hydrochloride
Αναλγητικό Ενέσιμο Morphine hydrochloride
Αντιμουσκαρινικό Ενέσιμο Scopolamine N-butyl bromide
Αναλγητικό Ενέσιμο Tramadol hydrochloride

  Mentions Légales